Novo's Non-Obesity Growth Forecasts Disappoint, Raising Doubts on Diversification

Novo Nordisk's plans to expand beyond weight-loss drugs appear underwhelming, with forecasts described as unambitious. This suggests limited near-term growth catalysts outside its core obesity franchise, potentially pressuring the stock. The market may reassess Novo's long-term growth narrative if diversification fails to materialize.